Trevena Inc TRVN
We take great care to ensure that the data presented and summarized in this overview for TREVENA INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TRVN
Top Purchases
Top Sells
About TRVN
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Insider Transactions at TRVN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 14
2023
|
Robert T Yoder SVP, Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,929
-1.2%
|
$0
$0.61 P/Share
|
|
Dec 14
2023
|
Robert T Yoder SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
117,500
+26.99%
|
$0
$0.61 P/Share
|
|
Dec 14
2023
|
Mark Demitrack SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,593
-1.16%
|
$0
$0.61 P/Share
|
|
Dec 14
2023
|
Mark Demitrack SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
235,000
+27.74%
|
$0
$0.61 P/Share
|
|
Dec 14
2023
|
Barry Shin SVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,616
-1.16%
|
$0
$0.61 P/Share
|
|
Dec 14
2023
|
Barry Shin SVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
235,000
+27.57%
|
$0
$0.61 P/Share
|
|
Dec 14
2023
|
Carrie L. Bourdow President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,123
-1.1%
|
$0
$0.61 P/Share
|
|
Dec 14
2023
|
Carrie L. Bourdow President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
470,000
+26.77%
|
$0
$0.61 P/Share
|
|
Dec 14
2023
|
Patricia M. Drake SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,835
-1.68%
|
$0
$0.61 P/Share
|
|
Dec 14
2023
|
Patricia M. Drake SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+28.0%
|
$0
$0.61 P/Share
|
|
Dec 02
2023
|
Mark Demitrack SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,211
-2.2%
|
$0
$0.59 P/Share
|
|
Dec 02
2023
|
Barry Shin SVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,036
-2.06%
|
$0
$0.59 P/Share
|
|
Dec 02
2023
|
Robert T Yoder SVP, Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,106
-2.27%
|
$0
$0.59 P/Share
|
|
Dec 02
2023
|
Carrie L. Bourdow President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,028
-2.12%
|
$0
$0.59 P/Share
|
|
Dec 02
2023
|
Patricia M. Drake SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-2.97%
|
$0
$0.59 P/Share
|
|
Sep 14
2023
|
Barry Shin SVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
72
-0.09%
|
$0
$0.7 P/Share
|
|
Jun 26
2023
|
Barry Shin SVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
722
-0.87%
|
$0
$0.84 P/Share
|
|
Jan 06
2023
|
Robert T Yoder SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+35.01%
|
-
|
|
Jan 06
2023
|
Mark Demitrack SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+38.45%
|
-
|
|
Jan 06
2023
|
Carrie L. Bourdow President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+34.24%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.13M shares |
|---|
| Payment of exercise price or tax liability | 46.4K shares |
|---|